Reference number : GC-2017-Q3-00487, amendment number : , agreement type : G, recipient legal name : Rogers, Michael (University of Guelph), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : In Canada, cannabis may be prescribed as a physician-recommended herbal therapy. While cannabis is typically_x000D_
smoked, inhalation of burned dry plant matter has obvious inherent health risks. Oral administration offers_x000D_
several key advantages, including elimination of pulmonary health risks and more accurate dosing of active_x000D_
ingredients such as THC and CBD. Oral administration does, however, suffer certain shortcomings and_x000D_
challenges as well. Bioavailability is defined as the proportion of a drug or other substance that enters_x000D_
circulation when introduced into the body and so is able to have an active effect. This is therefore an important_x000D_
property to assess when developing cannabis formulations for oral administration. Research has thus far shown_x000D_
that extensive liver metabolism reduces the oral bioavailability of THC to roughly 2-14%, while inhalation of_x000D_
marijuana smoke offers a systemic bioavailability generally ranging between 10-35%. Others have reported_x000D_
THC bioavailability after oral ingestion to be approximately 6% compared to 25% after smoking. The goal of_x000D_
our current research project is to develop novel formulations of cannabinoids in an effort to improve oral_x000D_
bioavailability. Assessing for bioavailability poses some serious challenges, as human or animal subjects are_x000D_
required and plasma samples must be drawn. The TIM-1 simulated in vitro gastrointestinal digestion model_x000D_
developed by TNO in the Netherlands is an advanced dissolution model with high correlation to in vivo testing_x000D_
and has been validated for use in drug delivery testing. Novel formulations can be assessed for bioavailability_x000D_
in a quick and cost-effective manner without the need for ethical approval when dealing with human or animal_x000D_
test subjects. This will allow rapid assessments of formulations and significantly increase the rate of innovation_x000D_
and discovery into enhancing oral bioavailability of cannabinoids., program purpose french : In Canada, cannabis may be prescribed as a physician-recommended herbal therapy. While cannabis is typically_x000D_
smoked, inhalation of burned dry plant matter has obvious inherent health risks. Oral administration offers_x000D_
several key advantages, including elimination of pulmonary health risks and more accurate dosing of active_x000D_
ingredients such as THC and CBD. Oral administration does, however, suffer certain shortcomings and_x000D_
challenges as well. Bioavailability is defined as the proportion of a drug or other substance that enters_x000D_
circulation when introduced into the body and so is able to have an active effect. This is therefore an important_x000D_
property to assess when developing cannabis formulations for oral administration. Research has thus far shown_x000D_
that extensive liver metabolism reduces the oral bioavailability of THC to roughly 2-14%, while inhalation of_x000D_
marijuana smoke offers a systemic bioavailability generally ranging between 10-35%. Others have reported_x000D_
THC bioavailability after oral ingestion to be approximately 6% compared to 25% after smoking. The goal of_x000D_
our current research project is to develop novel formulations of cannabinoids in an effort to improve oral_x000D_
bioavailability. Assessing for bioavailability poses some serious challenges, as human or animal subjects are_x000D_
required and plasma samples must be drawn. The TIM-1 simulated in vitro gastrointestinal digestion model_x000D_
developed by TNO in the Netherlands is an advanced dissolution model with high correlation to in vivo testing_x000D_
and has been validated for use in drug delivery testing. Novel formulations can be assessed for bioavailability_x000D_
in a quick and cost-effective manner without the need for ethical approval when dealing with human or animal_x000D_
test subjects. This will allow rapid assessments of formulations and significantly increase the rate of innovation_x000D_
and discovery into enhancing oral bioavailability of cannabinoids., agreement title english : Co-crystallization of hemp oil constituents and assessment for bioaccessibility using the TIM-1 in vitro gastrointestinal digestion model, agreement title french : Co-crystallization of hemp oil constituents and assessment for bioaccessibility using the TIM-1 in vitro gastrointestinal digestion model, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-12-13, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada